HIGHLIGHTS
- who: Yoshifumi Saisho from the Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan have published the research work: SGLT2 Inhibitors: The Star in the Treatment of Type Diabetes?, in the Journal: Diseases 8, 14 with2020, SGLT2 of /2020/
- what: SGLT2 inhibitors are a novel class of anti-diabetic medication that lowers plasma glucose level without hypoglycemia by increasing urinary glucose excretion.
- future: Patients considered for SGLT2 inhibitor treatment in the past the present and the future. Research is needed to clarify whether there is any difference in the effect on . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.